Tvardi Therapeutics (NASDAQ:TVRD) Raised to “Sell” at Wall Street Zen

Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.

Several other analysts also recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Wednesday, July 8th. HC Wainwright assumed coverage on Tvardi Therapeutics in a research note on Monday, June 8th. They set a “buy” rating and a $9.00 price objective on the stock. UBS Group upgraded Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective on the stock in a report on Wednesday, July 8th. Piper Sandler raised Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 target price for the company in a research note on Wednesday, July 8th. Finally, BTIG Research dropped their target price on Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Tvardi Therapeutics Stock Performance

Shares of TVRD opened at $1.87 on Friday. The firm has a market cap of $24.95 million, a price-to-earnings ratio of -0.67 and a beta of 0.32. Tvardi Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $43.65. The firm has a 50 day moving average price of $2.27 and a 200-day moving average price of $2.90.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). As a group, equities research analysts predict that Tvardi Therapeutics will post -2.35 earnings per share for the current year.

Hedge Funds Weigh In On Tvardi Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Jane Street Group LLC bought a new stake in shares of Tvardi Therapeutics in the fourth quarter worth about $204,000. Goldman Sachs Group Inc. raised its position in Tvardi Therapeutics by 37.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 33,131 shares of the company’s stock valued at $142,000 after purchasing an additional 9,102 shares during the last quarter. New York State Common Retirement Fund purchased a new stake in Tvardi Therapeutics in the 2nd quarter worth approximately $92,000. Quadrature Capital Ltd purchased a new stake in Tvardi Therapeutics in the 4th quarter worth approximately $90,000. Finally, Headlands Technologies LLC bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter worth approximately $80,000. 44.66% of the stock is owned by institutional investors.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.